Keros Therapeutics (KROS) Receivables - Net (2021 - 2025)
Keros Therapeutics' (KROS) quarterly Receivables - Net came in at $3.6 million in Q4 2025, up 30.09% YoY from $2.7 million in Q4 2024, and up 2.15% on a QoQ basis from $3.5 million in Q3 2025.
Keros Therapeutics (KROS) Receivables - Net (2021 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 4 years of Receivables - Net data on file, last reported at $3.6 million in Q4 2025.
- Quarterly Receivables - Net rose 30.09% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (up 30.09% YoY) and the FY2025 annual result came in at $3.6 million, up 30.09% from the prior year.
- Receivables - Net grew to $3.6 million in Q4 2025, from $3.5 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $18.0 million in Q4 2021 to a low of $4000.0 in Q2 2024.
- A 4-year average of $5.6 million and a median of $2.7 million in 2024 frame the typical range for Receivables - Net.
- The widest YoY moves for Receivables - Net: up 395300.0% in 2025, down 30.09% in 2025.
- Tracing KROS's Receivables - Net over 4 years: stood at $18.0 million in 2021, then slumped by 99.21% to $143000.0 in 2023, then jumped by 1817.48% to $2.7 million in 2024, then soared by 30.09% to $3.6 million in 2025.
- The last three Receivables - Net figures came in at $3.6 million (Q4 2025), $3.5 million (Q3 2025), and $15.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - |
| 10 | Keros Therapeutics | 216.02 Mn | -41.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.57 Mn |
| Dec 31, 2025 | 3.57 Mn |
| Sep 30, 2025 | 3.49 Mn |
| Sep 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | 15.82 Mn |
| Jun 30, 2025 | 15.82 Mn |
| Mar 31, 2025 | 17.29 Mn |
| Mar 31, 2025 | 17.29 Mn |
| Dec 31, 2024 | 2.74 Mn |
| Dec 31, 2024 | 2.74 Mn |
| Sep 30, 2024 | 388,000.00 |
| Sep 30, 2024 | 388,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 226,000.00 |
| Mar 31, 2024 | 226,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Dec 31, 2021 | 18.00 Mn |
| Dec 31, 2021 | 18.00 Mn |